D-RSC is currently working towards:

including clinical trials, registries and observational studies, which is partially available for

*Indicates disease with datasets that are currently discoverable on the platform

community since 2017.

of RDCA-DAP's advancements are possible without the participation of our

View all RDCA-DAP 2022 Webinars

March 15:

FDA/HHS or the U.S. Government.

of Health and Human Services (HHS) and is 55% funded by the FDA/HHS, totaling $17,612,250,

c-path.org/programs/rdca-dap

rdcadap@c-path.org

For questions or additional information about participating in RDCA-DAP, please email

An overview of CP-RND with feedback and questions from participants.

Clinical Outcome Assessment Consortium.

May 18:

Dr. Mark Sandridge, C-Path

Community After FTD Diagnosis

February 17, 2023:

February 28, 2023:

Accelerating Neurological Disease Research and Therapeutic Development

May 31, 2023:

June 2, 2023:

June 7, 2023:

We welcome anyone to

submitting poster abstracts on topics such as Innovative Research, Health Equity in Rare

interested stakeholders.

Duchenne Muscular Dystrophy Therapeutic Area User Guide, which is available to the

dystrophy and continues to work toward the expansion of available tools as more data is

Since launching the platform, we've seen the following engagement:

Member.

361 approved platform requests

of the rare disease community.

Disease Program will be more efficient in fulfilling the needs of, and communicating with,

announcements, webinars and meetings, this communication serves to update

conference will highlight the newly formed Rare and Orphan Disease Program within C-

C-Path's Rare and Orphan Disease Programs' impact on drug development in rare

impact and highlights

How RDCA-DAP has been enhanced in the last year, and how the platform informs

The Critical Path for Rare Neurodegenerative Disease (CP-RND) initiative's first year

diseases from the perspectives of patients, regulators and industry partners

Rare Disease Cures Accelerator-Data and Analytics Platform

Critical Path to Therapeutics for the Ataxias

Critical Path for Rare Neurodegenerative Diseases

Implementation of new data standard terminology for DMD and other

Regulatory acceptance of quantitative tools based on MRI biomarkers and other

Qualification of glutamate dehydrogenase as a liver safety biomarker in trials

Regulatory endorsements of the developed disease progression models of five

Spotlight: Duchenne Regulatory Science Consortium (D-RSC)

GNE Myopathy Rare Epilepsies*

Facioscapulohumeral muscular dystrophy

Duchenne Muscular Dystrophy* Phenylketonuria (PKU)*

Desmoid Tumor* Pemphigus & Pemphigoid*

Congenital Hyperinsulinism* Ocular Melanoma

Lennox-Gastaut Syndrome* Sturge-Weber Syndrome